Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by Snowballgrowthon Oct 17, 2020 2:38pm

76 Views

Post# 31734682

RE:RE:Q3 results

MrMugsy wrote: Good questions.

Where Knight goes with GBT all depends on how good the present strategy is ... and ... what the future strategy develops into. We don't have enough information to comment on it yet.

Goodman has had lots of success going into Africa so I'd bet we can do it again on a larger scale in LATAM. Hoping they are also building that relationship with M8 Pharma.

Too early to tell.
Too early to judge.
IMO.

Mug, many here think GBT is a fiasco, so they likely know something that you and me don't. They probably have an opinion about the futurs numbers. We are here to learn, aren't we ?

And we know nothing about Moksha8. I'm not sure we should hope for a relation or not.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide